Contact Us
Drug Search Results
More Filters [+]

ZEN-003694

Alternative Names: zen-003694, zen003694, zen 003694, zen-3694, zen 3694, zen3694
Latest Update: 2024-12-24
Latest Update Note: Clinical Trial Update

Product Description

ZEN-3694 is a novel BETi that inhibits proliferation of several cancer cell lines, and synergizes with various anti-cancer agents. (Sourced from: https://www.zenithepigenetics.com/upload/media_element/36/01/2015-aacr-eortc-poster.pdf)

Mechanisms of Action: BET Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Zenith Epigenetics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ZEN-003694

Countries in Clinic: China, United States

Active Clinical Trial Count: 8

Highest Development Phases

Phase 2: Adenocarcinoma|Fallopian Tube Cancer|Lung Cancer|Ovarian Cancer|Peritoneal Cancer|Prostate Cancer|Small Cell Lung Cancer|Triple Negative Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
HCC 21-091

P2

Recruiting

Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer

2029-12-01

NCI-2020-04495

P2

Recruiting

Small Cell Lung Cancer|Adenocarcinoma|Prostate Cancer

2027-04-30

NCT05607108

P2

Recruiting

Lung Cancer

2025-11-01

ZEN003694-500

P2

Enrolling by invitation

Prostate Cancer

2024-12-31

57%

Recent News Events

Date

Type

Title

03/18/2024

PubMed

 An LC-MS/MS method for determination of the bromodomain inhibitor ZEN-3694 and its metabolite ZEN-3791 in human plasma.

06/01/2023

News Article

 Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma

07/25/2022

News Article

 Combination Cancer Immunotherapy Market Opportunity and Clinical Trials Insights, 2028

07/06/2022

News Article

 Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials

06/23/2022

News Article

 The Worldwide Combination Cancer Immunotherapy Industry is Expected to Surpass $15 Billion by 2028

06/01/2022

PubMed

 Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer.

10/15/2020

PubMed

 A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions